Hepatitis C Treatments: Cure, Safety and Follow-Up

Hepatitis C treatments can cure the infection. Understanding the diagnosis, medicine review and follow-up plan helps you discuss the next step with your care team. ¹

Educational information checked against the listed sources on 14 October 2026. Treatment choices require an individual medical assessment. Read our medical disclaimer.

What hepatitis C treatment aims to achieve

Hepatitis C is an infection caused by the hepatitis C virus, often shortened to HCV. Modern treatment uses direct-acting antivirals, or DAAs, to target the virus. The goal is to clear the infection and reduce its consequences. A treatment decision also needs an assessment of existing liver damage. Clearing a virus and managing liver damage are related parts of care, but they are not interchangeable outcomes. There is no vaccine against hepatitis C. ¹

A short course can make a major difference

CDC reports that current oral DAA treatments cure more than 95% of people, commonly with eight to twelve weeks of therapy. Those figures describe treatment across suitable patients and regimens; they do not guarantee an individual result or establish the length of your prescription. Treatment is recommended for essentially everyone with hepatitis C, with important qualifications for particular circumstances. Current care does not require waiting months to see whether a newly diagnosed infection clears spontaneously. Older stories about interferon injections and their difficult side effects may describe a very different treatment era. Most current courses use oral medicines. A clinician still needs to establish which treatment fits your health history and to explain the follow-up that confirms its outcome. ²

Feeling well does not settle the question

Many people with hepatitis C have few or no symptoms, sometimes for years. Untreated chronic infection can lead to scarring of the liver, liver failure or liver cancer. Symptoms alone therefore cannot show whether infection is present or how much damage has occurred. NIDDK describes blood tests and assessment of the liver as parts of the diagnostic process. A clinician may use elastography, which measures liver stiffness, alongside other findings; biopsy is generally reserved for situations where other testing has not supplied enough information. If hepatitis C was mentioned at a previous appointment, it is worth finding the actual result and completing the assessment even when you feel healthy. The absence of symptoms is not a reason to assume that a positive result has resolved. ⁴

Start by deciding what you need answered at the first conversation. Someone who has just received a screening result needs an explanation of that result and the next diagnostic step. Someone already holding a prescription needs a practical plan for obtaining and taking it. Someone who finished a course needs the result of follow-up testing and a clear account of any remaining care. Tell the clinic which of these situations describes you. Bring the documents you have, even if they are incomplete, and identify the questions still unanswered. You do not need to arrive knowing the correct medicine. A useful goal for the visit is a written next step, the person responsible for arranging it and a way to check progress.

Confirming current infection before discussing medicines

A reactive hepatitis C antibody test shows that further interpretation is needed; it does not by itself establish current infection. An HCV RNA test looks for the virus. In its 2023 operational guidance, CDC recommends collecting the necessary samples at one visit and automatically performing RNA testing when the antibody test is reactive. This is often called reflex testing. A reactive antibody result without an RNA result is an incomplete testing sequence. Detectable RNA establishes current infection, whereas a reactive antibody result with undetectable RNA can reflect a resolved infection or, sometimes, a falsely reactive antibody test. Ask whether the laboratory completed both steps and who will explain the combined result. An isolated positive flag in a patient portal is less informative than the complete testing sequence. ³

Keep the original laboratory report with its collection date, test name, result and laboratory comments. If a telephone message simply said that the test was positive, ask which test the caller meant. Avoid rewriting a result from memory or assuming that every item marked abnormal refers to the same issue. If care has moved between clinics, request a copy for the new team and ask whether the earlier record has arrived. A one-page timeline can show when testing occurred, when a prescription was issued and whether treatment actually started. Use question marks for details you cannot verify. A candid gap in the history is more useful than a precise-looking date or medicine name that may be wrong.

How the main medicine options differ

Glecaprevir and pibrentasvir

Mavyret combines glecaprevir and pibrentasvir. Its June 2025 FDA label includes adults and children aged three years and older with acute or chronic HCV infection across genotypes one through six, without cirrhosis or with compensated, Child-Pugh A cirrhosis. It is contraindicated in Child-Pugh B or C disease or any previous hepatic decompensation. Genotypes are different forms of the virus. It also covers genotype one after a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both. This is not a universal retreatment indication. Pediatric formulation and treatment details depend on the child’s circumstances. This overview is not enough to select a course. The prescriber needs the exact treatment history and liver assessment, and the pharmacist should explain the supplied formulation. The label lists headache and fatigue among common adverse reactions. If a leaflet or website describes an older age threshold or chronic infection only, check its date against current prescribing information. ⁶

Sofosbuvir and velpatasvir

Epclusa combines sofosbuvir and velpatasvir. Its US label covers chronic HCV genotypes one through six in adults and children aged three years and older, without cirrhosis or with compensated cirrhosis. The label also includes use with ribavirin for decompensated cirrhosis, a substantially different clinical situation. That qualification matters: the same brand name does not mean that every patient follows the same plan. The prescribing information describes important interactions, including with acid-reducing medicines and amiodarone. These examples are reasons for a complete pharmacist review, not instructions to stop another prescription. Tell the team about products taken occasionally as well as daily medicines. Ask for instructions that match the exact products you use, including nonprescription heartburn remedies. A general treatment article cannot resolve these combinations safely for an individual. ⁷

A medicine used in selected retreatment situations

Vosevi contains sofosbuvir, velpatasvir and voxilaprevir. Its US indication is for adults with chronic HCV and no cirrhosis or compensated cirrhosis who have specified previous treatment histories. It includes genotypes one through six after an NS5A inhibitor regimen, and genotype one-a or three after a sofosbuvir-containing regimen without an NS5A inhibitor. It is not recommended in Child-Pugh B or C disease or any history of hepatic decompensation. This precision is why retreatment should not be selected from a list of brand names. A previous unsuccessful course, incomplete course and new infection are different histories to investigate. Provide the original medicine names and available results. A specialist can then evaluate the applicable options instead of assuming that a three-drug combination is automatically the best next choice. ⁸

If you cannot remember earlier treatment, begin with the pharmacy that dispensed it or the clinic that prescribed it. Ask for a medication history rather than guessing from tablet color or a television advertisement. Record whether the medicine was collected, whether you started it and what interrupted the plan, if anything. Keep practical details separate from conclusions: a late delivery is an event; a statement that the medicine failed is an interpretation for the clinical team to assess. Bring any remaining packaging or a clear photograph of its label. It is also useful to say what support was missing last time, such as help with refills, transport or understanding instructions, so the new plan can address that specific obstacle.

The safety checks that shape a treatment plan

Eligibility for a simplified pathway

Selected adults can use a simplified treatment pathway. Previous treatment, pregnancy, hepatitis B surface antigen positivity, suspected liver cancer or prior liver transplant can require another pathway. Cirrhosis has a separate algorithm; decompensated disease needs specialist care. Other pathways can still offer treatment. Pretreatment checks include liver and kidney function, infections and interactions. Treatment may be inappropriate when a short life expectancy cannot be improved by HCV therapy, transplantation or other directed care. ⁵

Understanding the liver assessment

Cirrhosis means that the liver has developed substantial scarring and damage. Its assessment draws on the medical history, examination, blood results and imaging. NIDDK explains that elastography estimates liver stiffness, while other imaging can show features of liver disease. A biopsy may be considered when the diagnosis remains uncertain. The history matters as well as the latest test: previous fluid buildup in the abdomen, internal bleeding or episodes of confusion should be reported to the team. These events need clinical interpretation, rather than a self-calculated score. Ask the clinician to write down how your liver condition has been classified and whether another specialist appointment is needed. Keep this explanation with your treatment documents so different teams have the same starting information. ¹²

Why hepatitis B testing is necessary

Hepatitis B and hepatitis C are different infections, but they can occur together. FDA warns that hepatitis B can reactivate during or after DAA treatment for hepatitis C in people with current or previous hepatitis B infection. Reported cases have included serious liver injury. FDA therefore requires prominent warnings and recommends screening and monitoring. A past hepatitis B diagnosis, even if described as inactive or resolved, belongs in the pretreatment discussion. This warning does not mean that everyone will reactivate or that effective hepatitis C care should be abandoned. It means that the team must identify the relevant history and arrange an appropriate management plan. Ask who is reviewing your hepatitis B results, whether additional care is needed and who will follow the plan after the hepatitis C course ends. ⁹

Advanced liver disease changes the options

FDA has reported rare serious liver injury with certain hepatitis C medicines in patients with advanced liver disease. The warning specifically concerns Mavyret, Zepatier and Vosevi and reinforces the need to assess liver disease before prescribing. A person who looks well at an appointment can still have an important history of liver complications. Tell the prescriber about previous hospital admissions, fluid drainage, bleeding or unexplained confusion, and provide discharge records when available. New jaundice, abdominal swelling or worsening symptoms during treatment should be reported promptly. Do not independently stop treatment because you have read a warning: obtain instructions from the treating clinician. The practical purpose of the warning is appropriate medicine selection and monitoring, not making readers choose among drugs without their clinical information. ¹⁰

A complete interaction review

The University of Liverpool’s hepatitis interaction resource evaluates combinations of antiviral drugs and other medicines. Its categories distinguish combinations to avoid, potential interactions needing management, weaker interactions and combinations where an interaction is not expected. Some assessments are based on predicted drug handling rather than direct studies, and a medicine missing from the database should not be assumed safe. The resource is useful for professional review, but a colored result is not a personal instruction to alter treatment. A pharmacist also needs the actual product, formulation and way you take it. Ask the team to document what was checked and explain any instructions in ordinary language. If another clinician later prescribes something new, make sure they know the hepatitis C treatment name and can coordinate with the treating team. ²¹

For the medication review, gather prescription labels, over-the-counter products, vitamins, herbal mixtures and anything bought online. Write down what you actually take, including occasional items, rather than copying an old list without checking it. If two containers have different names but you think they are the same product, bring both to the pharmacist. Mention difficulties reading small print, opening packaging or understanding the instructions. Ask for a copy of the final agreed list with the date of the review. Keep earlier versions separate so you can tell which instructions are current. When several clinicians are involved, identify one contact who can help resolve conflicting messages. Clear ownership of that question is more useful than trying to reconcile incompatible instructions yourself.

Circumstances that need additional coordination

HIV and hepatitis C together

Having HIV does not exclude someone from hepatitis C treatment. NIH guidance recommends evaluating people with HIV and HCV coinfection for curative HCV therapy and carefully reviewing interactions with antiretroviral treatment. HIV treatment remains important throughout this process. Some combinations require a coordinated change or additional monitoring, but that decision belongs to the clinicians managing the medicines. Do not interrupt antiretroviral therapy to make room for a hepatitis C prescription. The HIV team and hepatitis team should know what the other has prescribed, including any planned changes. Ask which clinician will review results and how both services will communicate. If care is being transferred, obtain a current treatment summary so that the receiving clinician can check the whole plan rather than evaluating each infection in isolation. ¹³

Kidney disease and transplantation

Kidney disease is another reason for tailored assessment rather than an assumption that hepatitis C cannot be treated. KDIGO’s 2022 guideline addresses DAA treatment across chronic kidney disease stages, including dialysis and kidney transplantation. It describes effective options while emphasizing treatment selection and interactions, especially with medicines used after transplantation. The kidney team should know the proposed antiviral plan and the hepatitis team should know the dialysis or transplant arrangements. Bring the latest medication list and tell both teams about planned procedures or changes in care. The timing of treatment around transplantation is a specialist decision. Advice written for someone with normal kidney function should not be applied without checking that it fits your circumstances. Likewise, older restrictions may not reflect current options. ²⁴

Pregnancy and planning a family

Pregnancy needs an individual discussion: routine DAA use is not established, while AASLD–IDSA allows consideration after weighing benefits and risks. Treatment before pregnancy is preferred when feasible. Ribavirin is contraindicated during pregnancy and carries precautions after exposure, including exposure through a male partner. Ask the specialist about the exact medicine and required precautions. ^{5, 25}

Why ribavirin has additional precautions

When ribavirin is part of a specialist plan, its safety requirements need a separate explanation. The medicine can cause hemolytic anemia, in which red blood cells are destroyed, and this can worsen heart disease. Its prescribing information also warns of serious risk to a developing pregnancy. Pregnancy prevention requirements continue for months after treatment and differ according to the product and whether exposure involves the patient or a male partner. Ask for the exact current instructions and the monitoring plan in writing. Do not rely on a remembered interval from an older leaflet or someone else’s prescription. Tell the team about relevant heart problems and discuss reproductive plans before treatment. If pregnancy is suspected during the applicable precaution period, contact the prescribing team promptly for individual advice. ²⁵

Children need their own assessment

A child exposed to hepatitis C around birth needs an age-appropriate testing plan. CDC’s 2023 recommendations include an HCV RNA test at age two to six months for perinatally exposed infants and specialist consultation for infants or children with detectable RNA. Older children who have not been tested follow different testing recommendations according to age. Early testing and later treatment eligibility are separate questions: the recommendation to test an infant does not mean that an adult medicine should be given to that infant. Keep the birth and testing records and ask the child’s clinician to explain the next step. If appointments have been missed or the child has changed caregivers, contact the pediatric team to reconstruct the plan rather than assuming that the opportunity for assessment has passed. ¹⁷

For pregnancy, parenting or caregiving, discuss how appointments fit around the people who depend on you. Ask whether visits can be combined, whether an interpreter is available and which questions can be handled remotely. If another adult helps with medicines or transport, decide what you want them to know and ask the clinic how they can be included with your permission. Keep your own questions visible during the appointment; another person’s understandable worry can otherwise take up the whole conversation. Request separate written instructions for each person receiving care. A parent’s plan and a child’s plan should each identify the responsible clinician, outstanding tests and next appointment, even when the same service is coordinating both.

Completing treatment in everyday life

Monitoring can be simpler for selected patients

The MINMON study investigated a deliberately simplified monitoring approach for hepatitis C treatment. This phase four, open-label, single-arm trial reported cure in 95% of 399 participants who started treatment. It tested a structured clinical approach, not unsupervised medicine use. The study included remote contact and a planned assessment of the outcome, with additional care available when needed. Because there was no randomized comparison group, its result should not be read as proof that every patient needs fewer visits or that monitoring can be omitted. Its practical importance is that services can consider reducing avoidable barriers for suitable patients while preserving clinical oversight. Ask why your own monitoring schedule was chosen and what should trigger contact between planned appointments. A shorter appointment schedule still needs a reliable way to obtain help. ¹⁸

Before the first dose, ask the pharmacy to walk through the instructions on the actual package and let you explain them back in your own words. Choose a reminder method you will notice and a place to keep the written instructions. A paper calendar, phone reminder or private checklist may fit better than an elaborate app. Discuss travel, shift work or an upcoming move before they become urgent. Confirm how refills will be delivered and what to do if the delivery address changes. If keeping medicines at home is difficult, say so directly; the team needs the real practical problem to help plan around it. Record the clinic and dispensing pharmacy numbers somewhere you can reach without searching through old messages.

If there is a missed dose, vomiting after a dose, lost medication or an unexpected interruption, contact the dispensing pharmacist or treatment team for instructions specific to your prescription. Have the medicine name, the timing of the problem and the number of doses involved ready. Say whether you have already received advice from someone else. Do not invent a catch-up schedule from another person’s experience. If the first contact is unavailable, use the service’s agreed backup route and keep a note of whom you spoke with. When instructions arrive, repeat them back and ask where they will be recorded. The aim is to solve the actual interruption promptly and make sure everyone is working from the same information.

Access, cost and support are part of treatment

WHO recommends simplifying hepatitis C service delivery through care closer to where people already receive support. Its guidance includes decentralization, integration with other services and sharing appropriate tasks with trained health workers. Depending on the local system, assessment and treatment may be available through primary care or community services rather than requiring every patient to attend a distant hospital. Complex circumstances still need the right expertise. If the referral you were offered is difficult to attend, ask whether a nearer service or coordinated appointment is possible. Availability differs between health systems, so an example from another country is not a promise about your local clinic. The useful question is which service can complete the necessary assessment and follow-through in a way you can realistically access. ¹⁶

Request a clear account of the steps between prescription and collection. Ask whether an authorization, referral, laboratory result or pharmacy enrollment is still outstanding, who is handling it and when you should check back. When cost is a concern, ask the clinic’s access staff to explain the options relevant to your location and coverage. Separate the medicine price from consultation, testing, travel and time away from work so you can discuss the actual obstacle. Keep application reference numbers and copies of requested documents. If an application is refused, ask for the reason in writing and whether the prescribing team can review the next step. Do not assume that a stalled administrative process is a medical decision that treatment is unsuitable.

Current drug use should not erase a treatment opportunity

The SIMPLIFY trial studied hepatitis C treatment in 103 people with recent injection drug use. Ninety-seven participants achieved sustained virologic response at twelve weeks after treatment, and the investigators reported no virologic failures. Some outcomes were affected by loss to follow-up or reinfection. This was an open-label, single-arm study, so it does not answer every question about every setting. It does, however, challenge the assumption that recent drug use makes successful treatment unattainable. The researchers concluded that treatment should be offered irrespective of ongoing drug use. The relevant conversation includes the support someone needs to complete care, receive results and reduce future exposure. A person’s disclosure of drug use should help the team plan appropriate care, rather than becoming a reason to avoid an honest discussion. ¹⁹

Syringe services programs can provide sterile equipment, safe disposal, infection testing and links to treatment or other support. CDC describes these services as community-based prevention programs that also connect people with care for substance use disorders. Their role is broader than handing out equipment: they can be an entry point for someone who has had difficulty reaching ordinary clinical services. Ask what is actually available locally, including whether hepatitis testing or treatment is offered on site or through a partner clinic. A referral is most useful when you know where to go, whom to contact and whether an appointment is required. If a service cannot provide one part of care, request help identifying the next service rather than assuming that the whole treatment pathway has ended. ²⁰

What cure means, and what happens afterward

Standard confirmation is an HCV RNA result showing sustained virologic response at least twelve weeks after treatment, called SVR12. Selected patients may use an earlier assessment under current guidance. Antibodies can remain positive after cure. Ongoing exposure risk calls for repeat RNA testing, not antibody testing alone. ⁵

Cure does not prevent another infection

Hepatitis C can be acquired more than once. The NHS advises avoiding shared injection or snorting equipment and personal items that may carry blood, such as razors and toothbrushes. Ordinary contact such as hugging, kissing or sharing food does not spread hepatitis C. A prevention conversation should therefore focus on relevant blood exposure without creating unnecessary distance from family or friends. Ask the team about your circumstances and any testing needed after a possible new exposure. The NHS also advises reporting treatment side effects and continuing follow-up testing to establish the outcome. Tiredness, headache or nausea can occur, but a symptom alone does not establish whether treatment has worked. Keep the laboratory follow-up separate from how you happen to feel on the day the course ends. ¹⁴

Cirrhosis can require continuing liver cancer surveillance

For people with cirrhosis who are candidates for liver cancer treatment, AASLD recommends ongoing surveillance, generally with liver ultrasound and an alpha-fetoprotein blood test about every six months. Hepatitis C cure does not automatically end that surveillance. The decision depends on the person’s overall condition and whether finding a cancer would lead to treatment; people with very advanced illness may need a different plan. AASLD does not recommend routine surveillance solely for advanced fibrosis without cirrhosis after HCV cure. This distinction needs a clinician’s assessment rather than an interpretation of a single laboratory number. Ask whether surveillance applies to you, when the next test is due and which service is responsible for arranging it. Screening appointments can otherwise be lost when antiviral treatment finishes and care transfers elsewhere. ¹¹

At the final treatment review, request a short summary that includes the medicine used, the actual course dates, the follow-up result and the next agreed action. Ask for a copy you can keep and one for your usual clinician. If a result is still pending, write down who will contact you and when you should follow up if no message arrives. Treat a move between clinics as a handover that needs confirmation: check that the receiving service has accepted the referral and can see the relevant records. You should leave knowing whether another appointment is booked, whether you need to arrange it yourself or whether the clinician has explicitly said that no further appointment is currently required.

Supporting liver health without unproven cures

Supplements cannot replace antiviral care

NCCIH reports that no dietary supplement has been shown effective for hepatitis C. Research on milk thistle has not established benefits against the infection, and colloidal silver can cause irreversible harm. A product described as natural is not automatically appropriate for someone with liver disease or an antiviral prescription. Supplement claims also need to distinguish treatment of a documented nutrient deficiency from treatment of a viral infection. Bring the exact ingredients and packaging to a pharmacist or clinician before using a product. Be cautious when a seller presents testimonials as proof, offers a guaranteed cure or recommends abandoning prescribed care. You do not need to buy a detox program to have a useful discussion about nutrition, comfort or practical support during treatment. Ask what the product is expected to achieve and what evidence supports that purpose. ¹⁵

Ask for support with alcohol when needed

If alcohol is difficult to control, support can include behavioral treatment, medication or mutual-support groups, selected for the individual. NIAAA emphasizes that alcohol use disorder is a medical condition and that recovery is possible. It also warns that suddenly stopping after prolonged heavy drinking can cause dangerous withdrawal. Tell the clinician about your usual intake and any previous withdrawal symptoms so that the next step can be planned safely. This is especially important when a discussion about liver health prompts an immediate decision to quit. Treatment for alcohol problems should be coordinated with the rest of your medical care. You do not have to work out an appropriate program or medicine alone. Ask for a named service and a practical way to contact it, rather than leaving with only a general instruction to change. ²²

For related background, see our guide to liver failure and specialist care and hepatitis A vaccine guide. Bring any questions about your own liver care or vaccination history to your clinician.

Choose a manageable set of questions for the next appointment instead of trying to solve every uncertainty at once. You might prioritize understanding the diagnosis, obtaining the prescription or clarifying the follow-up date. Write down what matters most to you, including privacy, travel, work, family responsibilities or previous difficulty accessing care. If you prefer explanations in another language or a different format, request that support when booking. Before leaving, review the agreed plan aloud and identify anything that still feels unclear. A useful treatment plan is one you can describe accurately, carry out in your actual circumstances and return to when a problem arises. Keep the contact details and next step alongside the documents, rather than relying on memory after a busy consultation.

Frequently asked questions

Can hepatitis C be cured?

Yes. Modern oral antivirals cure most people; testing after treatment confirms the individual result. ²

Does cure protect against reinfection?

No. A new exposure can cause another hepatitis C infection. ¹⁴

Why is hepatitis B checked before treatment?

Hepatitis B can reactivate during or after hepatitis C antiviral treatment. ⁹

What should I bring to the appointment?

Bring test reports, previous treatment details, your medicine and supplement list, and your main questions.